ATG12

Across TCGA pan-cancer cohorts, ATG12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATG12 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATG12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATG12 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, GBM, and LUAD are the cancer types where ATG12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	0.973	0.769	<.001	24	view →
GBM	OS	Median	All	0.268	0.512	.001	14	view →
LUAD	DFS	Quartile	II,III,IV	0.612	1.000	.022	7	view →
CCRCC	DFS	Median	All	0.605	0.862	.003	7	view →
PDAC	OS	Quartile	All	0.621	0.368	.022	6	view →
HNSC	DFS	Tertile	All	0.944	1.000	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATG12–UCEC (DFS)

Open the UCEC breakdown →